NewsBenzingaJohnson & Johnson Announces 1-Yr Results From Phase 3 FUZION Study Showing TREMFYA Maintained Or Improved Fistula Remission Through 48 Weeks In Adults With Crohn's Disease Johnson & Johnson Announces 1-Yr Results From Phase 3 FUZION Study Showing TREMFYA Maintained Or Improved Fistula Remission Through 48 Weeks In Adults With Crohn's Disease Benzinga 2026.10.19 12:08 (GMT+0) Open on Benzinga Other news Truist Securities Maintains Hold on M&T Bank, Lowers Price Target to $235 Truist Securities Maintains Buy on Inspired Entertainment, Lowers Price Target to $8 Truist Securities Maintains Buy on Gartner, Raises Price Target to $235 Wintrust Financial Q3 2026 Earnings Call Transcript MSCI Jumps After Q3 Revenue Beat Led by Its Index Business Steel Dynamics Q3 2026 Earnings Call Transcript
